Veterinary Medicines

Novomate 277.8 mg/ml powder and solvent for suspension for injection for cattle

Authorised
  • Penethamate hydriodide
Download as PDF

Product identification

Medicine name:
Novomate 277.8 mg/ml powder and solvent for suspension for injection for cattle
Novomate 277,8 mg/ml poeder en oplosmiddel voor suspensie voor injectie voor runderen
Active substance:
  • Penethamate hydriodide
Target species:
  • Cattle
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Penethamate hydriodide
    277.80
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Powder and solvent for suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Cattle
      • Meat and offal
        10
        day
      • Milk
        96
        hour
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01CE90
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Netherlands
Available in:
  • Netherlands
Package description:
  • Powder:Colourless, glass vials (siliconised) (50 ml) (type II) closed with rubber stoppers (bromobutyl) and aluminium caps.Solvent:Colourless, glass vials (50 ml) (type II) closed with rubber stoppers (bromobutyl) and aluminium caps.Pack sizes:Cardboard box with 1 pair of vials (10 g powder and 30 ml solvent)
  • Powder:Colourless, glass vials (siliconised) (30 ml) (type I) closed with rubber stoppers (bromobutyl) and aluminium caps.Solvent:Colourless, glass vials (20 ml) (type I) closed with rubber stoppers (bromobutyl) and aluminium caps.Pack sizes:Cardboard box with 6 pairs of vials (5 g powder and 15 ml solvent)
  • Powder:Colourless, glass vials (siliconised) (30 ml) (type I) closed with rubber stoppers (bromobutyl) and aluminium caps.Solvent:Colourless, glass vials (20 ml) (type I) closed with rubber stoppers (bromobutyl) and aluminium caps.Pack sizes:Cardboard box with 2 pairs of vials (5 g powder and 15 ml solvent)
  • Powder:Colourless, glass vials (siliconised) (30 ml) (type I) closed with rubber stoppers (bromobutyl) and aluminium caps.Solvent:Colourless, glass vials (20 ml) (type I) closed with rubber stoppers (bromobutyl) and aluminium caps.Pack sizes:Cardboard box with 1 pair of vials (5 g powder and 15 ml solvent)
  • Powder:Colourless, glass vials (siliconised) (50 ml) (type II) closed with rubber stoppers (bromobutyl) and aluminium caps.Solvent:Colourless, glass vials (50 ml) (type II) closed with rubber stoppers (bromobutyl) and aluminium caps.Pack sizes:Cardboard box with 6 pairs of vials (10 g powder and 30 ml solvent)
  • Powder:Colourless, glass vials (siliconised) (50 ml) (type II) closed with rubber stoppers (bromobutyl) and aluminium caps.Solvent:Colourless, glass vials (50 ml) (type II) closed with rubber stoppers (bromobutyl) and aluminium caps.Pack sizes:Cardboard box with 2 pairs of vials (10 g powder and 30 ml solvent)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Lohmann Pharma Herstellung GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Lohmann Pharma Herstellung GmbH
Responsible authority:
  • Medicines Evaluation Board
Authorisation number:
  • REG NL 115572
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0613/001
Concerned member states:
  • Austria
  • Belgium
  • Denmark
  • France
  • Netherlands
  • Poland
  • Portugal
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 11/05/2022
Download